Latest Articles

Publication Date
All News Scientific
Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study - MSN

Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study MSN

Published: Oct. 30, 2025, 10:49 a.m.
Read Full Article
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - BioSpace

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer BioSpace

Published: Oct. 28, 2025, 5:03 a.m.
Read Full Article
Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study - TipRanks

Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study TipRanks

Published: Oct. 27, 2025, 10:21 p.m.
Read Full Article
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment - TipRanks

Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 9:13 p.m.
Read Full Article
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal

Published: Oct. 27, 2025, 7:50 p.m.
Read Full Article
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Yahoo Finance

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Yahoo Finance

Published: Oct. 27, 2025, 7:33 p.m.
Read Full Article
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Business Wire

Published: Oct. 27, 2025, 7:33 p.m.
Read Full Article
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors - The Manila Times

Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors The Manila Times

Published: Oct. 24, 2025, 3:57 p.m.
Read Full Article
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - BioSpace

Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer BioSpace

Published: Oct. 21, 2025, 5:15 a.m.
Read Full Article
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal

Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal

Published: Oct. 20, 2025, 9:33 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!